𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease

✍ Scribed by Kitty K. Wong; Jane E. Alty; Amanda G. Goy; Sanjay Raghav; David C. Reutens; Peter A. Kempster

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
565 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background:

This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease.

Methods:

Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor subscale scoring were conducted on 1 day at the end of each treatment period.

Results:

Dyskinesia was slightly less on placebo (P = .26). Patient diary records also showed less dyskinesia on placebo (P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance (P = .05).

Conclusions:

Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties. © 2011 Movement Disorder Society

📜 SIMILAR VOLUMES

Sarizotan as a treatment for dyskinesias
Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial
✍ Christopher G. Goetz; Philippe Damier; Christine Hicking; Eugene Laska; Thomas M 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT~1A~ agonist properties and additio

A double blind randomized placebo contro
A double blind randomized placebo control trial of levetiracetam in tourette syndrome
✍ Constance L. Smith-Hicks; Dana D. Bridges; Nina P. Paynter; Harvey S. Singer 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract The objective of this study was to investigate the effectiveness of levetiracetam for the treatment of tics in children with Tourette syndrome (TS). Levetiracetam, an atypical anticonvulsant, has been suggested in open‐label protocols to be an effective tic‐suppressing agent in individu

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease
✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des

Randomized, placebo-controlled, double-b
Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease
✍ Andrea Martinuzzi; Alexandra Liava; Enrico Trevisi; Mara Frare; Caterina Tonon; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

## Abstract McArdle's disease causes limitation in exercise capacity as well as disability, the severity of which has been associated with the angiotensin‐converting enzyme (ACE) insertion (I)/deletion (D) haplotype—patients with the genotype associated with higher ACE activity show the most severe

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

Botulinum toxin type A for drooling in P
Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study
✍ Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Mari 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gla